Rational Drug Design Is An Approach To Discovering New Medications That Relies On Principles Of Molecular Modeling. This Method Of Drug Discovery Has Revolutionized The Pharmaceutical Industry By Providing A Systematic Approach To Understanding How Drugs Interact With Their Biological Targets, Enabling More Rapid And Effective Development Of New Treatments. The Rational Drug Design Process Begins With The Identification Of Molecular Targets Involved In A Disease Or Other Condition. This Target Is Then Studied To Determine Its Three-Dimensional Structure And How It Interacts With Compounds. The Structure Is Then Reproduced In A Computer Model, And Various Compounds Are Simulated To See Which Ones Bind To The Target With The Greatest Affinity. These Compounds Can Then Be Tested In Clinical Trials To Assess Their Efficacy And Safety In The Body. Rational Drug Design Has Significant Advantages Over Traditional Drug Discovery Methods. Most Notably, It Focuses On A Molecular Target Known To Be Involved In A Condition, Meaning That Medications Are Designed With A Much Greater Likelihood Of Being Effective. In Addition, Rational Drug Design Can Significantly Reduce The Amount Of Time Required For Drug Development And Reduce The Number Of Compounds Required For Testing. The Main Disadvantage To Rational Drug Design Is The Cost Associated With Creating And Testing The Computer Models. It Is Also A Fairly New Technology, And Therefore A Larger Amount Of Research And Development Must Be Conducted To Ensure The Accuracy Of The Models. In Addition, This Type Of Approach May Not Be Feasible For Some Conditions, As The Molecular Target Involved May Be Unknown Or Impossible To Model. Despite Its Challenges, Rational Drug Design Has Greatly Improved The Speed And Efficacy Of Drug Delivery. As Technology Further Develops, This Approach Will Continue To Be An Invaluable Method For Developing New Treatments For A Variety Of Conditions.
Title : Advances in plasma-based waste treatment for sustainable communities
Hossam A Gabbar, Ontario Tech University, Canada
Title : Nanostructured biodevices based on carbon nanotubes and glyconanoparticles for bioelectrocatalytic applications
Serge Cosnier, Silesian University of Technology, Poland
Title : Carbon capture and storage: The impact of impurities in CO2 streams
Andy Brown, Progressive Energy Ltd, United Kingdom
Title : Supramolecular nano chemistries: Fighting viruses, inhibiting bacteria and growing tissues
Thomas J Webster, Hebei University of Technology, China
Title : Chemical engineering of vanadium and tantalum zeolites for application in environmental catalysis
Stanislaw Dzwigaj, Sorbonne Universite, France
Title : Disrupting TNF-α and TNFR1 interaction: Computational insights into the potential of D-Pinitol as an anti-inflammatory therapeutic
Ferran Acuna Pares, Universidad Internacional de la Rioja (UNIR), Spain